Jump to content

Recommended Posts

Posted

Submitted without comment.
Connda

--------------------------------------

The Lancet Microbe
Jul 2021 Vol 2, Number 7, e279
COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room
Piero Olliaro,Els Torreele,Michel Vaillant

"Vaccine efficacy is generally reported as a relative risk reduction (RRR). It uses the relative risk (RR)—ie, the ratio of attack rates with and without a vaccine—which is expressed as 1–RR. Ranking by reported efficacy gives relative risk reductions of
95% for the Pfizer–BioNTech,
94% for the Moderna–NIH,
91% for the Gamaleya,
67% for the J&J,
and 67% for the AstraZeneca–Oxford vaccines.

However, RRR should be seen against the background risk of being infected and becoming ill with COVID-19, which varies between populations and over time.  Although the RRR considers only participants who could benefit from the vaccine, the absolute risk reduction (ARR), which is the difference between attack rates with and without a vaccine, considers the whole population.
ARRs tend to be ignored because they give a much less impressive effect size than RRRs:
1·3% for the AstraZeneca–Oxford,
1·2% for the Moderna–NIH,
1·2% for the J&J,
0·93% for the Gamaleya
and 0·84% for the Pfizer–BioNTech vaccines.

(HTML) https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00069-0/fulltext
(PDF) https://www.thelancet.com/pdfs/journals/lanmic/PIIS2666-5247(21)00069-0.pdf

  • Confused 1

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    • No registered users viewing this page.



×
×
  • Create New...